Labcorp announces 2022 second quarter results

Labcorp to spin off clinical development business

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 28, 2022-- Labcorp (NYSE: LH) (the “Company”), a leading global life sciences company, today announced that its Board of Directors has authorized the Company to pursue a spin-off of the Company’s wholly owned Clinical Development business to Labcorp shareholders through a tax-free transaction.

Labcorp earns top score on 2022 Disability Equality Index

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 22, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it scored 100, the highest score possible, on the 2022 Disability Equality Index® (DEI), a comprehensive benchmarking tool for measuring disability inclusion in the workplace.

New Labcorp test report helps identify insect stings and improve therapy decisions to combat allergic reactions

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 19, 2022-- Nearly 10 million people in the United States have a history of systemic or anaphylactic reaction to insect stings, with the risk of a severe and potentially life-threatening allergic reaction.